1. Home
  2. CINGW vs NHI Comparison

CINGW vs NHI Comparison

Compare CINGW & NHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • NHI
  • Stock Information
  • Founded
  • CINGW N/A
  • NHI 1991
  • Country
  • CINGW United States
  • NHI United States
  • Employees
  • CINGW 13
  • NHI N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • NHI Real Estate Investment Trusts
  • Sector
  • CINGW Health Care
  • NHI Real Estate
  • Exchange
  • CINGW Nasdaq
  • NHI Nasdaq
  • Market Cap
  • CINGW N/A
  • NHI N/A
  • IPO Year
  • CINGW 2021
  • NHI 1991
  • Fundamental
  • Price
  • CINGW $0.06
  • NHI $73.77
  • Analyst Decision
  • CINGW
  • NHI Buy
  • Analyst Count
  • CINGW 0
  • NHI 5
  • Target Price
  • CINGW N/A
  • NHI $82.20
  • AVG Volume (30 Days)
  • CINGW N/A
  • NHI 240.4K
  • Earning Date
  • CINGW N/A
  • NHI 05-05-2025
  • Dividend Yield
  • CINGW N/A
  • NHI 4.85%
  • EPS Growth
  • CINGW N/A
  • NHI 0.15
  • EPS
  • CINGW N/A
  • NHI 3.13
  • Revenue
  • CINGW N/A
  • NHI $335,583,000.00
  • Revenue This Year
  • CINGW N/A
  • NHI $10.57
  • Revenue Next Year
  • CINGW N/A
  • NHI $16.10
  • P/E Ratio
  • CINGW N/A
  • NHI $23.72
  • Revenue Growth
  • CINGW N/A
  • NHI 4.74
  • 52 Week Low
  • CINGW N/A
  • NHI $57.80
  • 52 Week High
  • CINGW N/A
  • NHI $86.13
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • NHI 52.56
  • Support Level
  • CINGW N/A
  • NHI $73.19
  • Resistance Level
  • CINGW N/A
  • NHI $74.97
  • Average True Range (ATR)
  • CINGW 0.00
  • NHI 1.40
  • MACD
  • CINGW 0.00
  • NHI -0.24
  • Stochastic Oscillator
  • CINGW 0.00
  • NHI 17.11

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: